Abstract
To examine whether increasing investment in needle/syringe exchange programs (NSPs) in the US would be cost-effective for HIV prevention, we modeled HIV incidence in hypothetical cases with higher NSP syringe supply than current levels, and estimated number of infections averted, cost per infection averted, treatment costs saved, and financial return on investment. We modified Pinkerton’s model, which was an adaptation of Kaplan’s simplified needle circulation theory model, to compare different syringe supply levels, account for syringes from non-NSP sources, and reflect reduction in syringe sharing and contamination. With an annual $10 to $50 million funding increase, 194–816 HIV infections would be averted (cost per infection averted $51,601–$61,302). Contrasted with HIV treatment cost savings alone, the rate of financial return on investment would be 7.58–6.38. Main and sensitivity analyses strongly suggest that it would be cost-saving for the US to invest in syringe exchange expansion.
Similar content being viewed by others
References
Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. JAIDS J Acquir Immune Defic Syndr. 2010;53:124–30.
Holtgrave DR, Wolitski RJ, Pals SL, Aidala A, Kidder DP, Vos D, et al. Cost–utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV. AIDS Behav. 2013;17:1626–31.
Hutchinson AB, Patel P, Sansom SL, Farnham PG, Sullivan TJ, Bennett B, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7:e1000342.
Centers for Disease Control and Prevention. HIV cost-effectiveness. http://www.cdc.gov/hiv/prevention/ongoing/costeffectiveness. 2014. Retrieved 2014 Apr 19.
Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6:e17502.
Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf.
Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: an economic evaluation of a local experience. Can Med Assoc J. 1997;157:255–62.
Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of Streetworks’ needle exchange program of Edmonton. Can J Public Health. 1999;90:168–71.
Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. JAIDS J Acquir Immune Defic Syndr. 2001;28:273–8.
Cabasés JM, Sánchez E. Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting. Eur J Health Econ. 2003;4:203–8.
Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov V, Emelyanova Z, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction. 2004;99:1565–76.
Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver’s supervised injection facility. Can Med Assoc J. 2008;179:1143–51.
Pinkerton SD. Is Vancouver Canada’s supervised injection facility cost-saving? Addiction. 2010;105:1429–36.
Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. Int J Drug Policy. 2005;16S:S31–44.
The Office of the Global AIDS Coordinator. PEPFAR blueprint: creating an AIDS-free generation. 2012. http://www.pepfar.gov/documents/organization/201386.pdf.
National Center for HIV/AIDS, Viral Hepatitis S and TP. Strategic Plan: Division of HIV/AIDS Prevention: 2011 through 2015. 2011. http://www.cdc.gov/hiv/pdf/policies_DHAP-strategic-plan.pdf.
Centers for Disease Control and Prevention. FY 2013 Full Year CR Operating Plan. http://www.cdc.gov/fmo/topic/Budget Information/appropriations_budget_form_pdf/FY2013_CDC_Full-Year_CR_Operating_Plan.pdf.
Health Omnibus Program Extensions of 1988 Act. http://history.nih.gov/research/downloads/PL100-607.pdf.
Barr S. Needle-exchange programs face new federal funding ban. Kaiser health news. 2011 Dec 21. http://www.kaiserhealthnews.org/stories/2011/December/21/needle-exchange-federal-funding.aspx.
Des Jarlais DC, Guardino V, Arasteh K, Mcknight C, Milliken J, Purchase D. Current state of syringe exchange in the known universe. 2010. Presentation at the National Syringe exchange Conference; 2010 Nov 17.
Tempalski B, Cooper HLF, Friedman SR, Des Jarlais DC, Brady JE, Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy. 2008;19(Suppl 1):S47–58.
Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. JAIDS J Acquir Immune Defic Syndr. 2007;45:108–14.
Office of Applied Studies SA and MHSA. Injection drug use and related risk behaviors. The NSDUH Report. 2009 Oct 29. http://www.samhsa.gov/data/2k9/139/139IDU.htm.
Des Jarlais DC, Pinkerton SD, Hagan H, Guardino V, Feelemyer J, Cooper HLF, et al. 30 Years on selected issues in the prevention of HIV among persons who inject drugs. Adv Prev Med. 2013;2013:346372.
Kahn JG. Are NEPs cost-effective in preventing HIV infection? In: Lurie P, Reingold AL, Bowser B, Chen D, Foley J, Guydish J, et al., editors. The public health impact of needle exchange programs in the United States and abroad. San Francisco: University of California; 1993. p. 477–511.
Kaplan EH, Brandeau ML. AIDS policy modeling by example. AIDS. 1994;8(Suppl 1):S333–40.
Kaplan EH. Economic analysis of needle exchange. AIDS. 1995;9:1113–9.
Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397–401.
Shafer KP, Hahn JA, Lum PJ, Ocha K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. JAIDS J Acquir Immune Defic Syndr. 2002;31:422–31.
Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80:iii7–14.
Poulin C, Alary M, Bernier F, Carbonneau D, Boily M-C, Joly JR. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among at-risk women, young sex workers, and street youth attending community organizations in Quebec City, Canada. Sex Transm Dis. 2001;28:437–43.
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Friedman SR. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug Alcohol Depend. 2009;101:88–91.
Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–54.
Friedman SR, Tempalski B, Cooper HLF, Perlis TE, Keem M, Friedman R, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81:377–400.
Brady JE, Friedman SR, Cooper HLF, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from to 2002. J Urban Health. 1992;2008(85):323–51.
Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of injection drug users in the United States to calculate National Rates of HIV Infection. 2012. Poster presentation at the 2012 National Summit on HIV Diagnosis, Prevention and Access to Care. http://www.hivforum.org/storage/hivforum/documents/_2012NationalSummit_Posting/c_115_lansky.pdf.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45.
Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S126–32.
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158:695–704.
McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25–9.
Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S37–44.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. JAIDS J Acquir Immune Defic Syndr. 2002;29:275–83.
Vickerman P, Hickman M, Rhodes T, Watts C. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. JAIDS J Acquir Immune Defic Syndr. 2006;42:355–61.
Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report Authors. 2008. http://www.nice.org.uk/nicemedia/pdf/NSPEconomicmodellingFullreportJune08.pdf. Retrieved 2012 Apr 3.
Bobashev GV, Zule WA, Morris RJ. Projecting sexual and injecting risks into future HIV outcomes with agent-based modeling. 2010. Poster presentation at the International AIDS Conference in Vienna, Austria, 2010. http://www.rti.org/pubs/bobashev_aids2010_poster.pdf.
National Research Council. Public financing and delivery of HIV/AIDS Care: securing the legacy of Ryan White. Washington, DC: The National Academies Press; 2005. http://www.iom.edu/Reports/2004/Public-Financing-and-Delivery-of-HIVAIDS-Care-Securing-the-Legacy-of-Ryan-White.aspx.
Acknowledgments
The authors acknowledge the valuable data from the annual surveys of NSPs which Beth Israel Medical Center and North American Syringe Exchange Network conduct with support from amFAR/The Foundation for AIDS Research using funding from the Elton John Foundation and the Irene Diamond-Tides Foundation. Trang Q. Nguyen acknowledges the funding from the Sommer Scholars Program, and Brian W. Weir acknowledges the funding from the National Institute on Drug Abuse (Grant F31 DA026763), for their doctoral training.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Nguyen, T.Q., Weir, B.W., Des Jarlais, D.C. et al. Syringe Exchange in the United States: A National Level Economic Evaluation of Hypothetical Increases in Investment. AIDS Behav 18, 2144–2155 (2014). https://doi.org/10.1007/s10461-014-0789-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-014-0789-9